Neoadjuvant Atezolizumab in Localized Bladder Cancer
Recruiting in Palo Alto (17 mi)
+2 other locations
LF
Overseen byLawrence Fong, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Lawrence Fong
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Approved in 2 Jurisdictions
Trial Summary
What is the purpose of this trial?
This phase II trial studies the best dose of atezolizumab in treating patients with bladder cancer that has not spread to other places in the body. Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Research Team
LF
Lawrence Fong, MD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
Inclusion Criteria
Ability to understand and willingness to sign informed consent
You are physically able to perform everyday activities without difficulty (ECOG performance status 0 or 1).
Your kidneys are not functioning properly, which will be determined by a test using your blood and urine.
See 18 more
Exclusion Criteria
Known hypersensitivity to CHO cell products or MPDL3280A formulation
You are pregnant or breastfeeding.
Primary TCC of the ureter, urethra, or renal pelvis without TCC of the bladder
See 19 more
Treatment Details
Interventions
- Atezolizumab (Checkpoint Inhibitor)
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Cohort A3: Atezolizumab Monotherapy (3 doses)Experimental Treatment1 Intervention
Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 3 cycles (1200 mg x 3 doses)
Group II: Cohort A2: Atezolizumab Monotherapy (2 doses)Experimental Treatment1 Intervention
Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 2 cycles (1200 mg x 2 doses)
Group III: Cohort A1: Atezolizumab (Single dose)Experimental Treatment1 Intervention
Atezolizumab will be given as a neoadjuvant treatment Intravenously (IV) on Day 1 of each 21-day Cycle, for up to 1 cycle (1200mg x 1 dose)
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of California, DavisDavis, CA
University of Southern CaliforniaLos Angeles, CA
University of California, San FranciscoSan Francisco, CA
Loading ...
Who Is Running the Clinical Trial?
Lawrence Fong
Lead Sponsor
Trials
6
Patients Recruited
90+
National Cancer Institute (NCI)
Collaborator
Trials
14080
Patients Recruited
41,180,000+
The V Foundation
Collaborator
Trials
10
Patients Recruited
320+
Bladder Cancer Advocacy Network
Collaborator
Trials
4
Patients Recruited
430+
Genentech, Inc.
Industry Sponsor
Trials
1578
Patients Recruited
569,000+
The Bladder Cancer Advocacy Network
Collaborator
Trials
1
Patients Recruited
20+
Conquer Cancer Foundation
Collaborator
Trials
22
Patients Recruited
4,000+